5,6-trans-16-ene-vitamin D3: A new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells

Cancer Research

Volumn 59, Issue 16, 1999, Pages 4023-4029

  Hisatake, Jun Ichi ^a   Kubota, Tetsuya ^a   Hisatake, Yasuko ^a   Uskokovic, Milan ^b   Tomoyasu, Shigeru ^c   Koeffler, H Phillip ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

^c SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; VITAMIN D DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CALCIUM BLOOD LEVEL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE S PHASE; CHEMICAL STRUCTURE; DRUG MECHANISM; INTRAPERITONEAL DRUG ADMINISTRATION; LEUKEMIA CELL LINE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL DIVISION; CHOLECALCIFEROL; FEMALE; HUMANS; LEUKEMIA, MYELOID; MALE; MICE; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0033566941     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. 3 receptors: gene regulation and genetic circuitry. FASEB J., 2: 3043-3053, 1988.
2. Eisman, J. A., Martin, T. J., MacIntyre, I., and Moseley, J. M. 1,25-Dihydroxyvitamin D receptor in breast cancer cells. Lancet, 2: 1335-1336, 1979.
3. 3 metabolites. Cancer Res., 43: 4443-4447, 1983.
4. Colston, K. W., Chander, S. K., Mackay, A. G., and Coombes, R. C. Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem. Pharmacol., 44: 693-702, 1992.
5. Bower, M., Colston, K. W., Stein, R. C., Hedley, A., Gazet, J. C., Ford, H. T., and Combes, R. C. Topical calcipotriol treatment in advanced breast cancer. Lancet, 337: 701-702, 1991.
6. 3 on the morphology of human breast cancer cell line BT.20. Differentiation, 40: 63-69, 1989.
7. 3 on primary cultures of human prostatic cells. Cancer Res., 54: 805-810, 1994.
8. 3. Endocrinology, 136: 20-26, 1995.
9. Danielpour, D., Kadomatsu, K., Anzano, M. A., Smith, J. M., and Sporn, M. B. Development and characterization of nontumorigenic and tumorigenic epithelial cell lines from rat dorsal-lateral prostate. Cancer Res., 54: 3413-3421, 1994.
10. 3 analogs and their 24-oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects. J. Cell Biochem., 66: 413-425, 1997.
11. 3. Proc. Natl. Acad. Sci. USA, 78: 4990-4994, 1981.
12. 3 prolong survival time of mice inoculated with myeloid leukemia cells. Proc. Natl. Acad. Sci. USA, 80: 201-204, 1983.
13. 3 prolongs survival time of leukemic mice. Proc. Natl. Acad. Sci. USA, 87: 3929-3932, 1990.
14. 3: differential effects on leukemic cell growth, differentiation, and intestinal calcium absorption. Cancer Res., 50: 6857-6864, 1990.
15. 3, inhibits azoxymethane-induced colonic tumorigenesis. Cancer Res., 55: 3050-3054, 1995.
16. 3. Cancer Res., 54: 4057-4064, 1994.
17. Yu, J., Papavasiliou, V., Rhim, J., Goltzman, D., and Kremer, R. Vitamin D analogs: new therapeutic agents for the treatment of squamous cancer and its associated hypercalcemia. Anticancer Drugs, 6: 101-108, 1995.
18. 3: towards an endocrine therapy of brain tumors? J. Neurosci. Res., 37: 271-277, 1994.
19. 3: in vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treat. Rep., 69: 1399-1407, 1985.
20. 3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia. Endocrinology, 129: 832-837, 1991.
21. 3 analog with potent ability to induce HL-60 cell differentiation without modulating calcium metabolism. Blood, 78: 75-82, 1991.
22. 3 is potent antileukemic agent with low potential to cause hypercalcemia. Leuk. Res., 18: 453-463, 1994.
23. 3 analogs: effect on leukemic clonal growth and differentiation and on serum calcium levels. Leuk. Res., 19: 65-72, 1995.
24. 3 analogs: a unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells. Cancer Res., 58: 3370-3375, 1998.
25. Anzano, M. A., Smith, J. M., Uskokovic, M. R., Peer, C. W., Mullen, L. T., Letterio, J. J., Welsh, M. C., Shrader, M. W., Logsdon, D. L., Driver, C. L., Brown, C. C., Roberts, A. B., and Sporn, M. B. 1α,25-Dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531), a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat. Cancer Res., 54: 1653-1656, 1994.
26. Munker, R., Kobayashi, T., Elstner, E., Norman, A. W., Uskokovic, M., Zhang, W., Andreeff, M., and Koeffler, H. P. A new series of vitamin D analogs is highly active for clonal inhibition, differentiation, and induction of WAF1 in myeloid leukemia. Blood, 88: 2201-2209, 1996.
27. 3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin. J. Mol. Endocrinol., 19: 15-27, 1997.
28. Ulaner, G. A., Hu, J. F., Vu, T. H., Giudice, L. C., and Hoffman, A. R. Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. Cancer Res., 58: 4168-4172, 1998.
29. Harley, C. B., Futcher, A. B., and Greider, C. W. Telomeres shorten during ageing of human fibroblasts. Nature (Lond.), 345: 458-460, 1990.
30. Allsopp, R. C., Vaziri, H., Patterson, C., Goldstein, S., Younglai, E. V., Futcher, A. B., Greider, C. W., and Harley, C. B. Telomere length predicts replicative capacity of human fibroblasts. Proc. Natl. Acad. Sci. USA, 89: 10114-10118, 1992.
31. Wright, W. E., and Shay, J. W. The two-stage mechanism controlling cellular senescence and immortalization. Exp. Gerontol., 27: 383-389, 1992.
32. Counter, C. M. The roles of telomeres and telomerase in cell life span. Mutat. Res., 366: 45-63, 1996.
33. de Lange, T. Telomeres and senescence: ending the debate. Science (Washington DC), 279: 334-335, 1998.
34. Sharma, H. W., Sokoloski, J. A., Perez, J. R., Maltese, J. Y., Sartorelli, A. C., Stein, C. A., Nichols, G., Khaled, Z., Telang, N. T., and Narayanan, R. Differentiation of immortal cells inhibits telomerase activity. Proc. Natl. Acad. Sci. USA, 92: 12343-12346, 1995.
35. Bestilny, L. J., Brown, C. B., Miura, Y., Robertson, L. D., and Riabowol, K. T. Selective inhibition of telomerase activity during terminal differentiation of immortal cell lines. Cancer Res., 56: 3796-3802, 1996.
36. Seol, J. G., Kim, E. S., Park, W. H., Jung, C. W., Kim, B. K., and Lee, Y. Y. Telomerase activity in acute myelogenous leukaemia: clinical and biological implications. Br. J. Haematol., 100: 156-165, 1998.
37. Nakayama, J., Tahara, H., Tahara, E., Saito, M., Ito, K., Nakamura, H., Nakanishi, T., Ide, T., and Ishikawa, F. Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat. Genet., 18: 65-68, 1998.
38. Nakamura, T. M., Morin, G. B., Chapman, K. B., Weinrich, S. L., Andrews, W. H., Lingner, J., Harley, C. B., and Cech, T. R. Telomerase catalytic subunit homologs from fission yeast and human. Science (Washington DC), 277: 955-959, 1997.
39. Meyerson, M., Counter, C. M., Eaton, E. N., Ellisen, L. W., Steiner, P., Caddle, S. D., Ziaugra, L., Beijersbergen, R. L., Davidoff, M. J., Liu, Q., Bacchetti, S., Haber, D. A., and Weinberg, R. A. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell, 90: 785-795, 1997.
40. Kilian, A., Bowtell, D. D., Abud, H. E., Hime, G. R., Venter, D. J., Keese, P. K., Duncan, E. L., Reddel, R. R., and Jefferson, R. A. Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Hum. Mol. Genet., 6: 2011-2019, 1997.
41. 3: a novel class of potent inhibitors of proliferation of human breast cell lines. Cancer Res., 57: 4545-4550, 1997.
42. Asou, H., Koike, M., Elstner, E., Cambell, M., Le, J., Uskokovic, M. R., Kamada, N., and Koeffler, H. P. 19-nor-Vitamin D analogs: a new class of potent inhibitors of proliferation and inducers of differentiation of human myeloid leukemia cell lines. Blood, 92: 2441-2449, 1998.
43. Jiang, H., Lin, I., Su, Z. Z., Collart, F. R., Huberman, E., and Fisher, P. B. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene, 9: 3397-3406, 1994.
44. 3 in HL60 cells. Cancer Res., 56: 264-267, 1996.
45. Rudolph, K. L., Chang, S., Lee, H. W., Blasco, M., Gottlieb, G. J., Greider, C., and DePinho, R. A. Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell, 96: 701-712, 1999.
46. Takakura, M., Kyo, S., Kanaya, T., Tanaka, M., and Inoue, M. Expression of human telomerase subunits and correlation with telomerase activity in cervical cancer. Cancer Res., 58: 1558-1561, 1998.
47. Snijders, P. J., van Duin, M., Walboomers, J. M., Steenbergen, R. D., Risse, E. K., Helmerhorst, T. J., Verheijen, R. H., and Meijer, C. J. Telomerase activity exclusively in cervical carcinomas and a subset of cervical intraepithelial neoplasia grade III lesions: strong association with elevated messenger RNA levels of its catalytic subunit and high-risk human papillomavirus DNA. Cancer Res., 58: 3812-3818, 1998.
48. Ramakrishnan, S., Eppenberger, U., Mueller, H., Shinkai, Y., and Narayanan, R. Expression profile of the putative catalytic subunit of the telomerase gene. Cancer Res., 58: 622-625, 1998.